Results 181 to 190 of about 7,693 (199)
Some of the next articles are maybe not open access.
Biochemical and Biophysical Research Communications, 2013
Small-molecule Bcl-2/Bcl-xL inhibitor Navitoclax represents a promising cancer therapeutic since preclinical and clinical studies with Navitoclax have demonstrated strong anticancer activity in several types of cancers. However, because Navitoclax has a low binding affinity to Mcl-1, anticancer activity by Navitoclax is often attenuated by the elevated
Gongquan, Li +7 more
exaly +3 more sources
Small-molecule Bcl-2/Bcl-xL inhibitor Navitoclax represents a promising cancer therapeutic since preclinical and clinical studies with Navitoclax have demonstrated strong anticancer activity in several types of cancers. However, because Navitoclax has a low binding affinity to Mcl-1, anticancer activity by Navitoclax is often attenuated by the elevated
Gongquan, Li +7 more
exaly +3 more sources
A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Molecular Cancer Therapeutics, 2010Abstract Evasion of apoptosis is a known feature of cancer cells. One mechanism of deregulating the apoptotic pathway is through overexpression of antiapoptotic BCL2 family members. ABT-263 (navitoclax) is a first-in-class BCL2 family inhibitor that restores the ability of cancer cells to undergo apoptosis.
Lloyd T, Lam +5 more
openaire +2 more sources
Acta BiomaterialiaCellular senescence is implicated in the occurrence and progression of multiple age-related disorders. In this context, the selective elimination of senescent cells, senolysis, has emerged as an effective therapeutic strategy. However, the heterogeneous senescent phenotype hinders the discovery of a universal and robust senescence biomarker that limits
Eva María Garrido García +2 more
exaly +6 more sources
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
2012A case history of the Abbott Oncology Bcl-2/Bcl-xL inhibitors program is presented. The target proteins interact with other members of the Bcl family through surfaces that are very large and hydrophobic even compared to other PPIs that have been targeted by pharma.
openaire +1 more source
Senolysis of bleomycin-induced senescent vestibular schwannoma cells by navitoclax
2023Trabajo presentado en Senestherapy-III: Cell senescence: mechanisms and therapies Meeting, celebrado el 07 de octubre de 2022.
openaire +1 more source
Orphan designation: navitoclax, Treatment of myelofibrosis
Case Medical Research, 2020openaire +1 more source